Answers are grounded in this paper and cite their sources.
Melanoma is the most dangerous type of skin cancer, largely due to its propensity for recurrence and metastasis, even after removal of malignant tissue. When melanoma reaches advanced stages, the disease becomes refractory to many types of therapy, which has created a need for novel therapeutic strategies to combat the disease. Our group focuses on the oncogenic function of a neuronal receptor, metabotropic glutamate receptor 1 (mGluR1). When mGluR1 is aberrantly expressed in melanocytes, elevated levels of extracellular glutamate mediate the constitutive activation of the receptor to promote cell proliferation. We are exploring the potential synergistic efficacy when combining a glutamatergic signaling inhibitor with a checkpoint inhibitor antibody
No takes yet. Share an insight, caveat, or question.
Suzie Chen (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: